🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Divi's Laboratories Limited DIVISLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.divislabs.com
Company Profile ↓
₹7,315.50
+7.37% 1Y
Mkt Cap₹1.94 L Cr
P/E75.61
P/B10.98
Div. Yield0.44%
52W High₹7,315.50
52W Low₹5,689.50
Book Value₹631.37
EPS (TTM)₹96.75

Company Overview

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.0%.

Consistent Profit Growth

Net profit has compounded at 12.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.3% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 24.3%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.04.

Recent Developments

  • Mar 2026 Revenue of ₹10,560.00 Cr (+12.8% YoY); net profit ₹2,568.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +12.8%, earnings +17.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.3%, profit CAGR 12.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.27%
1 Year:12.82%

Compounded Profit Growth

5 Years:12.08%
1 Year:17.21%

Stock Price Performance

1 Year:+7.37%
6 Months:+10.56%
3 Months:+16.24%
1 Month:+8.98%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹5,689.50 ₹7,315.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)74.83 · Overbought
Price Performance
1M+8.98%
3M+16.24%
6M+10.56%
1Y+7.37%
Valuation vs Sector

P/E of 75.61 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 24.3%.
  • Compounding revenue at 11.3% over 5 years.
  • Profit CAGR of 12.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 75.6.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
75.61
Industry PE
39.97
Forward P/E
51.96
PEG Ratio
-
Book Value
₹631.37
Price to Book
10.98
P/S
17.44
EV/EBITDA
52.50
Dividend Yield
0.44%

Growth (CAGR)

Revenue 5Y
11.27%
Profit 5Y
12.08%
Revenue (YoY)
12.82%
Earnings (YoY)
17.21%

Profitability & Returns

ROCE
18.96%
ROE
15.32%
ROA
12.82%
Profit Margin
24.32%
Op Margin
28.20%
Gross Margin
61.24%
EPS (Latest Qtr)
₹28.31
EPS (TTM)
₹96.75

Balance Sheet & Liquidity

Debt/Equity
0.04
Quick Ratio
3.50
Current Ratio
5.43
Debt
₹7.00 Cr
Total Assets
₹20,033.00 Cr
Current Assets
₹11,096.00 Cr
Working Capital
₹9,053.00 Cr

Ownership

Promoter Holding
52.00%
Chg in Prom Hold
-0.02%
FII / Inst Holding
29.70%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹1.94 L Cr
Total Revenue (TTM)
₹10,560.00 Cr
EBITDA
₹3,874.00 Cr
Free Cash Flow
₹218.00 Cr
Operating Cash Flow
₹2,738.00 Cr
Shares Outstanding
₹26.55 Cr
Gross Margin
61.24%
Payout Ratio
31.01%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
4 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
8 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,951.00 Cr1,778.00 Cr1,909.00 Cr1,855.00 Cr2,303.00 Cr2,118.00 Cr2,338.00 Cr2,319.00 Cr2,585.00 Cr2,410.00 Cr2,715.00 Cr2,604.00 Cr2,831.00 Cr
Cost of Revenue -------922.00 Cr981.00 Cr956.00 Cr-945.00 Cr1,119.00 Cr
Gross Profit -------1,397.00 Cr1,604.00 Cr1,454.00 Cr-1,659.00 Cr1,712.00 Cr
Operating Expenses 1,464.00 Cr1,274.00 Cr1,430.00 Cr1,366.00 Cr1,572.00 Cr1,496.00 Cr1,622.00 Cr753.00 Cr825.00 Cr837.00 Cr1,827.00 Cr887.00 Cr898.00 Cr
Operating Income 400.00 Cr411.00 Cr384.00 Cr394.00 Cr636.00 Cr525.00 Cr617.00 Cr644.00 Cr779.00 Cr617.00 Cr775.00 Cr772.00 Cr814.00 Cr
EBITDA 487.00 Cr504.00 Cr479.00 Cr489.00 Cr731.00 Cr622.00 Cr716.00 Cr825.00 Cr972.00 Cr848.00 Cr888.00 Cr904.00 Cr1,089.00 Cr
Interest Expense 001.00 Cr02.00 Cr01.00 Cr01.00 Cr3.00 Cr8.00 Cr6.00 Cr6.00 Cr
Pretax Income 466.00 Cr492.00 Cr469.00 Cr489.00 Cr713.00 Cr604.00 Cr722.00 Cr726.00 Cr864.00 Cr733.00 Cr912.00 Cr780.00 Cr963.00 Cr
Tax Provision 144.46 Cr137.76 Cr121.94 Cr132.03 Cr178.25 Cr175.16 Cr209.38 Cr137.00 Cr202.00 Cr188.00 Cr218.88 Cr197.00 Cr212.00 Cr
Net Income 321.00 Cr356.00 Cr348.00 Cr358.00 Cr538.00 Cr430.00 Cr510.00 Cr589.00 Cr662.00 Cr545.00 Cr689.00 Cr583.00 Cr751.00 Cr
Diluted EPS 12.0913.4113.1113.4920.2716.2019.2122.2024.9320.4925.9521.9828.31

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,115.00 Cr3,776.00 Cr4,064.00 Cr3,891.00 Cr4,946.00 Cr5,394.00 Cr6,969.00 Cr-7,665.00 Cr7,796.00 Cr9,360.00 Cr10,560.00 Cr
Cost of Revenue --------3,178.00 Cr3,269.00 Cr3,725.00 Cr4,093.00 Cr
Gross Profit --------4,487.00 Cr4,527.00 Cr5,635.00 Cr6,467.00 Cr
Operating Expenses 1,942.00 Cr2,354.00 Cr2,615.00 Cr2,622.00 Cr3,072.00 Cr3,568.00 Cr4,102.00 Cr-2,460.00 Cr2,695.00 Cr3,069.00 Cr3,489.00 Cr
Operating Income 1,037.00 Cr1,305.00 Cr1,327.00 Cr1,127.00 Cr1,705.00 Cr1,640.00 Cr2,611.00 Cr-2,027.00 Cr1,832.00 Cr2,566.00 Cr2,978.00 Cr
EBITDA 1,173.00 Cr1,423.00 Cr1,450.00 Cr1,269.00 Cr1,874.00 Cr1,826.00 Cr2,867.00 Cr-2,712.00 Cr2,544.00 Cr3,320.00 Cr3,874.00 Cr
Interest Expense 3.00 Cr5.00 Cr3.00 Cr2.00 Cr5.00 Cr7.00 Cr2.00 Cr-03.00 Cr2.00 Cr23.00 Cr
Pretax Income 1,072.00 Cr1,393.00 Cr1,395.00 Cr1,231.00 Cr1,855.00 Cr1,819.00 Cr2,666.00 Cr-2,369.00 Cr2,163.00 Cr2,916.00 Cr3,388.00 Cr
Tax Provision 225.12 Cr264.67 Cr334.80 Cr356.99 Cr500.85 Cr436.56 Cr693.16 Cr-545.00 Cr563.00 Cr725.00 Cr820.00 Cr
Net Income 852.00 Cr1,126.00 Cr1,060.00 Cr877.00 Cr1,353.00 Cr1,377.00 Cr1,984.00 Cr-1,824.00 Cr1,600.00 Cr2,191.00 Cr2,568.00 Cr
Diluted EPS 32.0742.4139.9533.0450.9651.8574.75-68.6960.2782.5396.75

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 4,405.00 Cr4,898.00 Cr6,155.00 Cr6,785.00 Cr8,036.00 Cr8,531.00 Cr10,771.00 Cr-14,439.00 Cr15,470.00 Cr16,932.00 Cr20,033.00 Cr
Current Assets --------9,312.00 Cr9,675.00 Cr10,081.00 Cr11,096.00 Cr
Cash & Equivalents --------170.00 Cr363.00 Cr415.00 Cr128.00 Cr
Inventory --------3,000.00 Cr3,184.00 Cr3,236.00 Cr3,954.00 Cr
Receivables --------1,793.00 Cr2,156.00 Cr2,731.00 Cr2,984.00 Cr
Total Liabilities --------1,672.00 Cr1,899.00 Cr1,963.00 Cr3,272.00 Cr
Current Liabilities --------1,101.00 Cr1,278.00 Cr1,452.00 Cr2,043.00 Cr
Long Term Debt ------------
Total Debt 27.00 Cr42.00 Cr36.00 Cr63.00 Cr106.00 Cr39.00 Cr5.00 Cr-4.00 Cr3.00 Cr4.00 Cr7.00 Cr
Total Equity 3,496.00 Cr4,293.00 Cr5,357.00 Cr5,925.00 Cr6,957.00 Cr7,310.00 Cr9,295.00 Cr-12,767.00 Cr13,571.00 Cr14,969.00 Cr16,761.00 Cr
Shares Outstanding --------26.55 Cr26.55 Cr26.55 Cr26.55 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 826.00 Cr1,038.00 Cr1,150.00 Cr776.00 Cr954.00 Cr1,216.00 Cr1,947.00 Cr-2,459.00 Cr1,261.00 Cr1,653.00 Cr2,738.00 Cr
Investing Cash Flow -521.00 Cr-406.00 Cr-1,140.00 Cr-478.00 Cr-685.00 Cr-83.00 Cr75.00 Cr--2,707.00 Cr-269.00 Cr-804.00 Cr-2,219.00 Cr
Financing Cash Flow -303.00 Cr-631.00 Cr2.00 Cr-314.00 Cr-246.00 Cr-1,091.00 Cr-35.00 Cr--797.00 Cr-799.00 Cr-799.00 Cr-804.00 Cr
Capital Expenditure -307.00 Cr-396.00 Cr-376.00 Cr-274.00 Cr-733.00 Cr-1,183.00 Cr-910.00 Cr--473.00 Cr-1,003.00 Cr-1,438.00 Cr-2,520.00 Cr
Free Cash Flow 519.00 Cr642.00 Cr774.00 Cr502.00 Cr221.00 Cr33.00 Cr1,037.00 Cr-1,986.00 Cr258.00 Cr215.00 Cr218.00 Cr
Net Change in Cash 3.00 Cr013.00 Cr-17.00 Cr23.00 Cr41.00 Cr1,987.00 Cr--1,045.00 Cr193.00 Cr50.00 Cr-285.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------58.5%58.1%60.2%61.2%
Operating Margin % 33.3%34.6%32.7%29.0%34.5%30.4%37.5%-26.4%23.5%27.4%28.2%
Net Margin % 27.4%29.8%26.1%22.5%27.4%25.5%28.5%-23.8%20.5%23.4%24.3%
ROE % 24.4%26.2%19.8%14.8%19.4%18.8%21.3%-14.3%11.8%14.6%15.3%
ROCE % --------15.2%12.9%16.6%16.6%

Shareholding Pattern

Insiders
52.00%
Institutions
29.70%
Public Float
61.87%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DIVISLAB

Google News Sun, 12 Jul 2026

Divis Lab Q4 Results 2026 | Divis Lab Results Today | Divis Lab Share Latest News Tornado (DJTFCtxMdY) - Mshale

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5BdHNDS2I4dXZPMVBFTmd1cjgzRnktNU9OWjMxN1NEQldRa0liX1hMU0VZV21oTjRZOU9yZk9BWXByZWVTMk8xY3JKbXMxV0RsYzNmY1NTYUFieUU?oc=5" target="_blank">Divis Lab Q4 Results 2026 | Divis Lab Result…

Google News ue, 14 Jul 2026

Indian Export Stocks That Look Better Placed If US Tariffs Rise - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOanF2dGYxYS1PUkhXand4LUQxZFhLdGJLZHZYWkNKR0pkS1hycTN6NG5DYy0yT2tpeEhlTjg4Vm5VM2tjSjUwMHJCQk9IekNKU1JFNkVBVEwwbTlfRXRJVFYxNzV0Q3FYMnJPTVhXZWdvVGk5ZWJUNTBTYU1PWDRWR09KN2wtS1M3VElWX1…

Google News Fri, 10 Jul 2026

DIVISLAB Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTFB1ZmszR2lvV2t2S2dES3Z6Uy1PenR6SkRHUmp2QmRiS0U2ZHJWWERCQ0hKRTNKV2hiMUhGQzAwTFp6dVZXbE5JT0UzSy1BdEhwanpYd0FEd3ZTRy1vZi1va1ZOUkU1UnI5YU04?oc=5" target="_blank">DIVISLAB Outlook for th…

Google News Mon, 13 Jul 2026

Divi's Laboratories Recommends ₹30 Final Dividend for FYa26; Shares Slip 0.42% - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNazlCbDUtWTJIaUx6SmtzaXpSY19xNHlOcDQyUEd4UGVoQzJBbkw0cXMtMjctTjMyaGo1dG40bVdUNFV5MVVETTFMRWtpeGdGWTR0Vk9jRWdtN0U4eUVBWUVkeC1BdF9lTm5qQVdaQ25UV1FaNUVaa1lhRG9DTkZ1N1BLZ2dqTWQyR2xJQg…

Google News Sun, 24 May 2026

Accumulate Divi's Laboratories; target of Rs 6900: Prabhudas Lilladher - TradingView

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxObEFrd0gwSElQM0taOGJINEg5bTJHM0VKR2ZJMk94NlhYTzNpSFgxVmVxb0s4Z0oxYnpYUHJlN3NrdlJsNDBfWkJUc2dfcjQyQURoMElUYThNUVRWUDZfelNueXhPUUNvdWNVMW1mNjJDSnVIYVVKTURFNDVxbnRmTC1TYUlGS0V4YjRvMk…

Google News ue, 26 May 2026

Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQRDRqS2FRbkx6Q3h2bnJLZm5Ha2JRVDdzaDloYThYekhfQTZXeVJuV3F0QmotU2c0RE9WMUxaUWtPdGxLYmd2QWN4cEc0RVZBYnJBRmhIQTJhNVMzOWQxS3ZKUk9VcXhFUHFSVjltb3RQWE5GV3pjWmdwOVZDWDdkY3l2clJNRjNTYlpocl…

DIVISLAB — Frequently Asked Questions

What is the current share price of Divi's Laboratories Limited (DIVISLAB)?

As of 2026-07-15 09:52 IST, Divi's Laboratories Limited (DIVISLAB) trades at ₹7,315.50 on NSE. Its 52-week range is ₹5,689.50 to ₹7,315.50.

What is the market capitalisation of DIVISLAB?

Divi's Laboratories Limited (DIVISLAB) has a market capitalisation of ₹1.94 L Cr on NSE.

What is the P/E ratio of DIVISLAB?

DIVISLAB trades at a trailing price-to-earnings (P/E) ratio of 75.61. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 10.98.

Does DIVISLAB pay a dividend?

Divi's Laboratories Limited (DIVISLAB) currently offers a dividend yield of 0.44%.

What is the return on equity (ROE) of DIVISLAB?

DIVISLAB has a return on equity (ROE) of 15.32%. Its return on capital employed (ROCE) is 18.96%.

Is DIVISLAB a good stock to buy?

This page provides a data-driven analysis of Divi's Laboratories Limited (DIVISLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space